View Older Stories
-
Elanco Animal Health (ELAN) Reiterated at Buy by Stifel on Lowered Sales Estimates
-
Elanco Animal Health (ELAN): UBS Confident of 'Catalyst-Rich Story in 2026'
-
Elanco Animal Health (ELAN) Reiterated at Buy by Stifel On Continued Upside Bias
-
This company is set up well for 2026, says KeyBanc
-
'Elanco Animal Health (ELAN) set up well for beats and raises'; PT Raised to $29 at KeyBanc
-
Elanco Animal Health (ELAN) PT Raised to $30 at BofA Securities
-
Elanco Animal Health (ELAN) PT Raised to $30 at Leerink Partners
-
Elanco Animal Health (ELAN) Tops Q4 EPS by 2c ; Offers Guidance
-
Elanco Animal Health (ELAN) call put ratio 1 call to 1.6 puts
-
Piper Sandler Upgrades Elanco Animal Health (ELAN) to Overweight
-
Increasing unusual call option volume: EIX EWJ BRKR ELAN WSM BNC ENTG OGN
-
Elanco receives USDA approval for canine dermatitis treatment Befrena
-
Elanco Animal Health's (ELAN) Price Increases Estimate for 2026 is +3-4% - Stifel
-
Elanco receives first FDA conditional approval for screwworm treatment
-
KeyBanc sees a buying opportunity in this pet stock
-
Elanco Animal Health (ELAN) Can Drive +MSD% Revenue Growth - Stifel
-
KeyBanc on Elanco Animal Health (ELAN): 'We See Buying Opportunity with Stock Pullback'
-
Elanco Animal Health (ELAN) PT Raised to $26 at Leerink Partners
-
Elanco outlines growth targets and restructuring plan at investor day
-
Increasing unusual call option volume: ELAN JBS HLF NVRI
-
Elanco receives FDA emergency authorization for cat screwworm treatment
-
KeyBanc Starts Elanco Animal Health (ELAN) at Overweight
-
Elanco Animal Health (ELAN) Revenue Growth Estimates Raised at Stifel
-
Elanco Animal Health (ELAN) PT Raised to $25 at Leerink Partners
-
Elanco Animal Health (ELAN) Tops Q3 EPS by 6c, Beats on Revenue; Offers FY25 Guidance
-
Elanco Animal Health (ELAN) 4800 contracts of January 20 puts trade
-
Elanco gets FDA approval for expanded Credelio labels against Lyme disease
-
Elanco gets FDA emergency authorization for screwworm treatment in dogs
-
JPMorgan Upgrades Elanco Animal Health (ELAN) to Overweight
-
Elanco Animal Health (ELAN) PT Raised to $23 at Stifel
-
Elanco Innovation Builds Momentum, Credelio Quattro(TM) (Lotilaner, Moxidectin, Praziquantel, and Pyrantel Chewable Tablets) Reaches Blockbuster Status
-
Elanco's Credelio Quattro reaches $100 million in sales milestone
-
Elanco to join S&P MidCap 400 as Sarepta moves to SmallCap 600
-
Elanco Animal Health (ELAN) Tops Q2 EPS by 6c ; Offers Guidance
-
Elanco receives EU approval for canine dermatitis drug Zenrelia
-
Leerink Partners Upgrades Elanco Animal Health (ELAN) to Outperform
-
Elanco gets USDA approval for canine influenza vaccine TruCan Ultra CIV
-
This stock is Stifel's 'Best Idea in Animal Health' sector
-
Elanco Animal Health (ELAN) PT Raised to $17 at Stifel
-
Elanco Releases 2024 Impact Report and Introduces New Framework
-
William Blair Upgrades Elanco Animal Health (ELAN) to Outperform 'on Improving Growth Outlook'
-
TD Cowen's Best Smidcap Ideas 2025
-
Elanco Animal Health (ELAN) Receives Positive Opinion on Zenrelia (ilunocitinib) from EU's Committee for Veterinary Medicinal Products
-
Elanco Animal Health (ELAN) PT Raised to $14.50 at Leerink Partners
-
Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief
-
Elanco Animal Health (ELAN) Appoints Robert VanHimbergen as CFO
-
Elanco Animal Health (ELAN) PT Raised to $15 at TD Cowen
-
Elanco Animal Health (ELAN) PT Raised to $15 at Stifel
-
Elanco Animal Health (ELAN) Tops Q1 EPS by 6c ; Offers Guidance
-
Elanco Animal Health (ELAN) sells certain royalties and commercial milestones associated with XDEMVY to Blackstone Life Sciences and Blackstone Credit & Insurance for $295M Cash

